In 2024, the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) took significant compliance efforts to safeguard drug quality and public health. This C-realize series opener highlights some notable inspections and warning letters.
These actions show the importance of good manufacturing and distribution practices together with data integrity for biopharmaceutical and medical device companies globally. Want to know more about these? Check out the full post for an in-depth look.